Tailoring Treatment in Cardiovascular Diseases: The Role of Targeted Therapies

• Published in: Pharmaceutics Vol. 16; no. 4; p. 461
• Main Authors: Dankar, Razan, Wehbi, Jad, Refaat, Marwan M
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 26-03-2024; MDPI
• Subjects: Atherosclerosis; bispecific antibodies (BsAbs); Blood platelets; Cardiovascular disease; cell therapy; Cholesterol; Clinical trials; Coronary vessels; Drug dosages; FDA approval; Heart attacks; Kinases; Lipids; Lipoproteins; Monoclonal antibodies; monoclonal antibodies (mAbs); Mortality; Mutation; nucleic acid drugs; Patients; Review; Statins; targeted therapy; Vein & artery diseases; cardiovascular disease; targeted therapy; nanoparticles; cell therapy; monoclonal antibodies (mAbs); nucleic acid drugs; precision medicine; bispecific antibodies (BsAbs)
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics16040461

Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality around the globe. To address this public health burden, innovative therapeutic agents are being developed to specifically target molecular and genetic markers. Various therapeutic modalities have been implemented, including vaccines, monoclonal or bispecific antibodies, and gene-based therapies. Such drugs precisely target the underlying disease pathophysiology, aiming at notable molecules such as lipid metabolism regulators, proinflammatory cytokines, and growth factors. This review focuses on the latest advancements in different targeted therapies. It provides an insightful overview of the current landscape of targeted cardiovascular therapies, highlighting promising strategies with potential to transform the treatment of CVDs into an era of precision medicine.